Health Economics›Multiple myeloma›Relapsed or refractory triplets

Relapsed or refractory triplets

Multiple myeloma · 39 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 22 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Dara-Kd Variant #01	—	R 1 295 339	28d	~28.5 mo	~50.8 mo	~7	~R 2 839 860 PFS proxy · indirect	3
Dara-Pd Variant #01	—	R 618 681	28d	~8.4 mo	—	~8	~R 1 748 539 PFS proxy · indirect	2
Dara-Rd Variant #01	—	R 592 167	28d	~53.2 mo	~67.6 mo	~8	~R 1 536 423 PFS proxy · indirect	6
SDd Variant #01 Partial	—	R 589 989	28d	—	—	~8	~R 1 518 999 indirect	—
Ven-Kd Variant #01	—	R 370 559	28d	—	—	~3	~R 861 191 indirect	—
Dara-Vd Variant #01	—	R 344 395	28d	~10.6 mo	~49.6 mo	~8	~R 1 323 169 PFS proxy · indirect	6
Isa-Kd Variant #01 Partial	—	R 284 265	28d	~35.7 mo	—	~3	~R 444 453 PFS proxy · indirect	1
SKd Variant #01 Partial	—	R 198 943	28d	—	—	~10	~R 714 924 indirect	—
Dara-Kd (SC daratumumab) Variant #01 Partial	—	R 175 215	28d	—	—	~8	~R 773 143 indirect	—
KRd Variant #08	—	R 152 564	28d	~34.6 mo	~48.3 mo	~12	~R 981 397 PFS proxy · indirect	6
KPD Variant #01	—	R 80 082	28d	—	—	~7	~R 560 576 indirect	—
IRd Variant #03	—	R 65 423	28d	~13.7 mo	~25.8 mo	~18	~R 748 807 PFS proxy · indirect	5
BID Variant #01	—	R 38 404	28d	—	—	~8	~R 307 230 indirect	—
PVD Variant #01	—	R 30 313	28d	~11.8 mo	—	~10	~R 258 391 PFS proxy · indirect	5
Elo-Pd Variant #01 Partial	—	R 29 821	28d	~7.4 mo	~29.8 mo	~4	~R 117 027 PFS proxy · indirect	3
PCD Variant #01	—	R 29 642	28d	~10.9 mo	—	~9	~R 263 217 PFS proxy · indirect	1
BPd Variant #01 Partial	—	R 29 040	28d	—	—	~3	~R 87 119 PFS proxy · indirect	1
Isa-Pd Variant #01 Partial	—	R 29 040	28d	~11.5 mo	~24.6 mo	~3	~R 87 119 PFS proxy · indirect	3
Dara-Pd (SC daratumumab) Variant #01 Partial	—	R 29 040	28d	~11.8 mo	—	~8	~R 232 318 PFS proxy · indirect	4
PCP Variant #01	—	R 24 036	28d	—	—	~6	~R 144 217 indirect	—
CTD Variant #01	—	R 19 552	21d	—	—	~10	~R 86 855 indirect	—
RVD Variant #07	—	R 17 832	21d	~43.0 mo	—	~39	~R 415 913 PFS proxy · indirect	9
VDC Variant #01	—	R 15 305	28d	~30.0 mo	—	~3	~R 45 914 PFS proxy · indirect	1
Elo-Vd Variant #01 Partial	—	R 14 438	28d	~9.7 mo	—	~8	~R 72 919 PFS proxy · indirect	2
VTD Variant #01	—	R 13 365	21d	~35.8 mo	—	~2	~R 26 730 PFS proxy · indirect	1
BBD Variant #01	—	R 12 422	28d	—	—	~8	~R 99 378 indirect	—
Bortezomib and Dexamethasone (Vd) and Panobinostat Variant #01 Partial	—	R 11 185	21d	~12.0 mo	—	~16	~R 89 477 PFS proxy · indirect	1
BTD Variant #01	—	R 11 031	28d	—	—	~9	~R 99 275 indirect	—
BLD Variant #01	—	R 7 838	28d	—	—	~8	~R 62 706 indirect	—
SVd Variant #01 Partial	—	R 7 630	35d	~13.9 mo	—	~2	~R 15 260 PFS proxy · indirect	1
BVd Variant #01 Partial	—	R 7 456	21d	—	—	~9	~R 59 651 PFS proxy · indirect	2
Dara-Vd (SC daratumumab) Variant #01 Partial	—	R 7 456	21d	—	—	~8	~R 59 651 PFS proxy · indirect	1
PAD Variant #01	—	R 7 335	21d	~35.0 mo	—	~8	~R 58 677 PFS proxy · indirect	2
Elo-Rd Variant #01 Partial	—	R 6 660	28d	~19.4 mo	~48.3 mo	~4	~R 24 210 PFS proxy · indirect	2
ZRd Variant #01 Partial	—	R 5 792	28d	—	—	~2	~R 11 584 indirect	—
Dara-Rd (SC daratumumab) Variant #01 Partial	—	R 5 792	28d	~38.0 mo	—	~8	~R 44 255 PFS proxy · indirect	2
CPR Variant #01	—	R 5 726	28d	~20.0 mo	—	~10	~R 57 260 PFS proxy · indirect	2
FRD Variant #01 Partial	—	R 5 705	28d	—	—	~2	~R 11 411 indirect	—
CRd Variant #03	—	R 3 754	28d	—	—	~12	~R 45 051 indirect	—

39 of 39 regimens shown